Lindahl advises BrainCool on raising capital of approximately SEK 70.7 million

Lindahl has acted as legal adviser to BrainCool AB (publ) in connection with the company's rights issue, which was completed on 17 December 2025. The rights issue was oversubscribed, which led the board of directors to decide to utilise part of the possible over-allotment issue.

The rights issue raised approximately SEK 42.2 million for BrainCool, before deduction of issue costs. In light of the strong interest, the Board of Directors decided, with the support of an authorisation from the Extraordinary General Meeting on 26 November 2025, to carry out an over-allotment issue of approximately SEK 28.5 million. In total, the company thus raised approximately SEK 70.7 million in issue proceeds before deduction of costs.

The capital raising is intended to support BrainCool's continued commercial development, including sales development of the IQool® System, further development of the RhinoChill® System and strengthening the company's working capital.

Lindahl's team consisted of Erika Svensson, Anna Drogou and Emelie Carmhagen.

About our client BrainCool

BrainCool AB (publ) is a medical technology company that develops innovative medical cooling systems with the aim of saving lives and reducing healthcare-related injuries in conditions such as cardiac arrest, stroke and chemotherapy-related side effects. The company's shares are listed on Nasdaq First North Growth Market in Stockholm.

Capital Markets | Public M&A

Lindahl assists companies with stock market listings, issuances, and regulations within the securities market.

Related cases & articles